TY - JOUR T1 - Review: maximum androgen blockade does not confer additional survival benefit to androgen suppression in prostate cancer JF - Evidence Based Medicine JO - Evid Based Med SP - 17 LP - 17 DO - 10.1136/ebm.6.1.17 VL - 6 IS - 1 A2 - , Y1 - 2001/01/01 UR - http://ebm.bmj.com/content/6/1/17.abstract N2 - (2000) Lancet 355, 1491. Prostate Cancer Trialists' Collaborative Group.. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials.. Apr 29;. :. –8. .OpenUrlCrossRefPubMedWeb of Science
 
 QUESTION: In men with prostate cancer, is maximum androgen blockade (MAB) better than androgen suppression (AS) alone for prolonging survival? Studies were identified by searching computerised databases, trial registers, meeting abstracts, and reference lists and by contacting investigators and pharmaceutical companies. Studies were selected if they were randomised trials that began before 1991 and compared MAB (AS plus an antiandrogen, such as nilutamide, flutamide, or cyproterone acetate) with AS alone and if the treatment was given for ≥1 year. Information was requested for each patient on stage of disease, age at randomisation, date of randomisation, treatment allocation, date of last follow up, date of death, and cause of death. 1 trials … ER -